The structure of Atalanta Therapeutics’ RNA interference drugs enables them to distribute broadly and deeply into brain tissue. Lead programs for Huntington’s disease and a rare inherited form epilepsy are on track to enter the clinic this year.
The post RNAi Biotech Atalanta Unveils $97M to Reach the Clinic in Two Rare Neuro Diseases appeared first on MedCity News.
